Cohlhepp Ryan 4

What Happened Ryan Cohlhepp, President & COO and a director of Bicara Therapeutics (BCAX), was granted 300,000 derivative shares in a compensatory award reported on Feb 2, 2026. The Form 4 reports the acquisition at $0.00 (total reported value $0); the filing describes the award as an option-type derivative that will convert to shares as it vests. This is a grant/award (code A) — a compensation/retention tool rather than an immediate purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (timely filing).
• Transaction type/code: Grant/Award (A) of 300,000 derivative securities.
• Reported price: $0.00 (filing lists acquisition value $0).
• Vesting: Footnote F1 — the shares underlying this option vest in 16 equal quarterly installments beginning Feb 2, 2026 (16 quarters = 4 years), subject to continued service.
• Shares owned after transaction: not specified in the provided filing details.
• No sale, exercise, or tax-withholding reported in this filing.

Context This is a typical executive equity award intended for retention and incentive; because it vests over time, it does not represent immediate insider buying or selling. Such grants are common in executive compensation and should be viewed as part of overall pay structure rather than a direct market sentiment signal. Retail investors who want more detail should review the company’s proxy or 10-K for executive compensation policies and future disclosures about exercises or actual share issuances.